![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/GLAND.png)
Share the post "Gland Pharma ‘s Q3 2024-25 Latest News: Revenue Falls by 10.43% YoY"
Highlights
🔹 The presented financial data is Consolidated to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company’s sales declined by -10.43 % over the year, decrease in net sales/revenue by -1.55 %. 🔹 Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 56.44 %. Marginal decrease of -1.95% in other income during this quarter. 🔹 Profit over the Year and quarter: Significant improvement in profitability for Gland Pharma Limited. Notable increase of 6.69 % in net profit Year to Year, Gland Pharma Limited’s profitability increased by 25.17 % in this quarter. 🔹 EPS over the Year and quarter: EPS increased by 6.61 % Year to Year. EPS increased by 25.08 % in previous quarter. Positive impact on shareholders.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 1545.155 Cr | Rs. 1405.833 Cr | Rs. 1384.052 Cr | -1.55 % | -10.43 % |
| Expenses | Rs. 1188.77 Cr | Rs. 1108.78 Cr | Rs. 1024.1 Cr | -7.64 % | -13.85 % |
| Operating Profit | Rs. 356.39 Cr | Rs. 297.05 Cr | Rs. 359.95 Cr | + 21.17 % | + 1 % |
| OPM % | 23.06 % | 21.13 % | 26.01 % | + 4.88 % | + 2.95 % |
| Other Income | Rs. 37.391 Cr | Rs. 59.659 Cr | Rs. 58.494 Cr | -1.95 % | + 56.44 % |
| Interest | Rs. 5.28 Cr | Rs. 6.11 Cr | Rs. 22.82 Cr | + 273.49 % | + 332.2 % |
| Depreciation | Rs. 105.34 Cr | Rs. 93.83 Cr | Rs. 96.33 Cr | + 2.66 % | -8.55 % |
| Profit before tax | Rs. 283.16 Cr | Rs. 256.77 Cr | Rs. 299.29 Cr | + 16.56 % | + 5.7 % |
| Tax % | 32.24 % | 36.31 % | 31.61 % | -4.7 % | -0.63 % |
| Net Profit | Rs. 191.86 Cr | Rs. 163.53 Cr | Rs. 204.69 Cr | + 25.17 % | + 6.69 % |
| EPS in Rs | Rs. 11.65 | Rs. 9.93 | Rs. 12.42 | + 25.08 % | + 6.61 % |
Today, we’re looking at Gland Pharma Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a significant year-over-year sales decline of -10.43 %. However, it did see a marginal slip of -1.55 % from the previous quarter. Expenses decreased slightly by -7.64 % quarter-on-quarter, aligning with the annual decline of -13.85 %. Operating profit, while up 1 % compared to last year, faced a quarter-on-quarter increase of 21.17 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 2.95 %, but an expansion of 4.88 % sequentially. Other income fell by -1.95 % compared to the last quarter, despite an annual growth of 56.44 %. Interest expenses surged remarkably by 273.49 % from the previous quarter, yet the year-over-year increase remains at a moderate 332.2 %. Depreciation costs climbed by 2.66 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -8.55 %. Profit before tax grew annually by 5.7 % but saw an increase from the preceding quarter by 16.56 %.
Tax expenses as a percentage of profits decreased slightly by -0.63 % compared to last year, with a more notable quarter-on-quarter decrease of -4.7 %. Net profit rose by 6.69 % year-on-year but experienced a 25.17 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 6.61 % but a quarterly rise of 25.08 %. In summary, Gland Pharma Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 1545.155 Cr | Rs. 1405.833 Cr | Rs. 1384.052 Cr | -1.55 % | -10.43 % |
| Expenses | Rs. 1188.77 Cr | Rs. 1108.78 Cr | Rs. 1024.1 Cr | -7.64 % | -13.85 % |
| Operating Profit | Rs. 356.39 Cr | Rs. 297.05 Cr | Rs. 359.95 Cr | + 21.17 % | + 1 % |
| Net Profit | Rs. 191.86 Cr | Rs. 163.53 Cr | Rs. 204.69 Cr | + 25.17 % | + 6.69 % |
| EPS in Rs | Rs. 11.65 | Rs. 9.93 | Rs. 12.42 | + 25.08 % | + 6.61 % |
In reviewing Gland Pharma Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -10.43 % year-on-year, although there was a slight dip of -1.55 % from the previous quarter. Expenses decreased by -13.85 % compared to the previous year, with a decrease of -7.64 % quarter-on-quarter. Operating Profit surged by 1 % annually, and saw a 21.17 % increase from the last quarter.
Net Profit showed yearly increase of 6.69 %, and experienced a 25.17 % increase from the previous quarter. Earnings Per Share (EPS) rose by 6.61 % annually, however rose by 25.08 % compared to the last quarter. In essence, while Gland Pharma Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
